💫 Phase 3 #KEYNOTE756 trial - 1⃣st interim analysis: 💫
✅ Pembro + chemo ⬆️ pCR in high-risk early ER+/HER2− #BreastCancer (24.3% 🆚 15.6%)
⚠️ Manageable safety
📊 EFS data maturing
📰 Read more: nature.com/articles/s41...
@oncoalert.bsky.social
7
3
0
0